Abstract
Background: Essential oils (EOs) and their volatile components (VCs) have varied biological and pharmacological activities, but low solubility and bioavailability hamper their applications, so that inclusion in cyclodextrins (CDs) is likely to improve their physicochemical properties and pharmacological effects.
Objective: The authors conducted a systematic review to evaluate the biological activities and pharmacological applications of essential oils and their volatile components complexed with cyclodextrins.
Methods: The search terms 'Cyxlodextrin', 'Inclusion Complex', 'Volatile oils', 'Essential oil' and 'Volatile components' were used to retrieve articles from the PUBMED, MEDLINE and SCOPUS databases.
Results: A total of 38 articles were identified. A greater efficacy of EOs and their VCs complexed with different CDs types was found in in vitro and preclinical studies when compared to free forms in the various biological activities and animal models of the evaluated pharmacological tests.
Conclusion: This review of selected studies showed that the use of CDs promotes greater solubility, bioavailability and efficacy of EOs and their VCs, thus indicating an interesting alternative for the biotechnological development of new therapeutic formulations.
Keywords: Cyclodextrin, volatile oils, essential oils, inclusion complex, biological activities, pharmacological application, systematic review.
Current Pharmaceutical Design
Title:Biological Activities and Pharmacological Applications of Cyclodextrins Complexed with Essential Oils and Their Volatile Components: A Systematic Review
Volume: 24 Issue: 33
Author(s): Rosueti Diógenes de Oliveira-Filho*, Angelo Roncalli Avles e Silva, Renato de Azevedo Moreira and Nadia Accioly Pinto Nogueira
Affiliation:
- Laboratory of Applied Microbiology, Department of Clinical and Toxicological Analysis, Federal University of Ceará (UFC), Fortaleza, Ceara,Brazil
Keywords: Cyclodextrin, volatile oils, essential oils, inclusion complex, biological activities, pharmacological application, systematic review.
Abstract: Background: Essential oils (EOs) and their volatile components (VCs) have varied biological and pharmacological activities, but low solubility and bioavailability hamper their applications, so that inclusion in cyclodextrins (CDs) is likely to improve their physicochemical properties and pharmacological effects.
Objective: The authors conducted a systematic review to evaluate the biological activities and pharmacological applications of essential oils and their volatile components complexed with cyclodextrins.
Methods: The search terms 'Cyxlodextrin', 'Inclusion Complex', 'Volatile oils', 'Essential oil' and 'Volatile components' were used to retrieve articles from the PUBMED, MEDLINE and SCOPUS databases.
Results: A total of 38 articles were identified. A greater efficacy of EOs and their VCs complexed with different CDs types was found in in vitro and preclinical studies when compared to free forms in the various biological activities and animal models of the evaluated pharmacological tests.
Conclusion: This review of selected studies showed that the use of CDs promotes greater solubility, bioavailability and efficacy of EOs and their VCs, thus indicating an interesting alternative for the biotechnological development of new therapeutic formulations.
Export Options
About this article
Cite this article as:
de Oliveira-Filho Diógenes Rosueti *, e Silva Roncalli Avles Angelo , de Azevedo Moreira Renato and Nogueira Accioly Pinto Nadia , Biological Activities and Pharmacological Applications of Cyclodextrins Complexed with Essential Oils and Their Volatile Components: A Systematic Review, Current Pharmaceutical Design 2018; 24 (33) . https://dx.doi.org/10.2174/1381612824666181120093634
DOI https://dx.doi.org/10.2174/1381612824666181120093634 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements